Vitro Obtains US Adult Stem Cell Patent

Vitro declared that it has received US Patent number 7527971 entitled, “Generation and Differentiation of Adult Stem Cells.”

The patent provides protection to a specific cell line derived from human pancreatic tissues that gives rise to structures comparable to the Islets of Langerhans.

Moreover, Vitro has also developed a process for the commercial production its cell line-derived islets. Furthermore, the company previously obtained regulatory approval for an animal protocol to determine reversal of Type I diabetes. Thus, the recently issued patent affords an exclusive proprietary position to the company for a new cellular therapy to treat Type I diabetes.

Jim Musick, President and CEO of Vitro, said: “We are pleased to announce the issuance of our new patent from the USPTO. We intend to develop our patented technology into a viable therapy for Type I diabetes. Our issued US patents now include production of FSH, a fertility drug, methods and compositions for production of immortalized human cells, and adult stem cells.”